FDA Chief Admits He Overhyped Plasma Treatment Against COVID: ‘Criticism Is Entirely Justified’

FDA Commissioner Stephen Hahn looks during a coronavirus press briefing, in the James Brady Press Briefing Room at the White House March 19, 2020 in Washington, DC. (Photo by Brendan Smialowski / AFP) (Photo by BREND... FDA Commissioner Stephen Hahn looks during a coronavirus press briefing, in the James Brady Press Briefing Room at the White House March 19, 2020 in Washington, DC. (Photo by Brendan Smialowski / AFP) (Photo by BRENDAN SMIALOWSKI/AFP via Getty Images) MORE LESS

Food and Drug Administration Commissioner Stephen Hahn conceded on Monday night that he had exaggerated the effectiveness of convalescent plasma therapy as treatment for COVID-19 the day before.

“I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma. The criticism is entirely justified,” Hahn tweeted. “What I should have said better is that the data show a relative risk reduction not an absolute risk reduction.”

The official clarified that the agency’s emergency approval of the treatment “is not a final approval” and that FDA scientists will “continue to monitor its use and will revoke authorization if needed.”

“We feel broader use of plasma will truly benefit many patients but will require further study,” he tweeted.

Hahn also denied that the authorization, which had been touted by President Donald Trump in his desperate efforts to bolster his reelection chances, was motivated by politics even as Trump pressures the FDA to approve treatment by November.

“We at FDA do not permit politics to enter into our scientific decisions,” Hahn tweeted. “This happens to be a political season but FDA will remain data driven.”

During a press briefing with Trump on Sunday, Hahn had heaped praise upon convalescent plasma therapy, claiming it had reduced the mortality rate among COVID-19 by as much as 35 percent.

“We dream in drug development of something like a 35 percent mortality reduction,” the FDA official said. “This is a major advance in the treatment of patients. This is a major advance.”

Dear Reader,

When we asked recently what makes TPM different from other outlets, readers cited factors like honesty, curiosity, transparency, and our vibrant community. They also pointed to our ability to report on important stories and trends long before they are picked up by mainstream outlets; our ability to contextualize information within the arc of history; and our focus on the real-world consequences of the news.

Our unique approach to reporting and presenting the news, however, wouldn’t be possible without our readers’ support. That’s not just marketing speak, it’s true: our work would literally not be possible without readers deciding to become members. Not only does member support account for more than 80% of TPM’s revenue, our members have helped us build an engaged and informed community. Many of our best stories were born from reader tips and valuable member feedback.

We do what other news outlets can’t or won’t do because our members’ support gives us real independence.

If you enjoy reading TPM and value what we do, become a member today.

Latest News
Comments
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Reporters:
Newswriters:
Director of Audience:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: